CDX2 and carcinoma: However, it remains unclear whether SATB2 is differently expressed within purely morphological (adenocarcinoma NOS vs. specific CRC subtypes, tumour budding subcategories (Bd1/2/3), WHO low- vs. high-grade carcinomas), immunohistochemical (CDX2 expression) and pTNM/UICC stage subgroups.